Area of research
Immunology · Oncology
Research interest
Research interests include Medicine, Trametinib, Clinical endpoint, Internal medicine, Gynecology, and Dabrafenib.
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”
S3‐Leitlinie ,,Diagnostik, Therapie und Nachsorge des Melanoms” – Kurzfassung
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600E/K </sub>mutant advanced or metastatic melanoma (MM).